CTX 101

Drug Profile

CTX 101

Alternative Names: AlloCSC 01; Allogenic cardiac stem cells - Coretherapix; CTX-101

Latest Information Update: 21 Jun 2016

Price : $50

At a glance

  • Originator Coretherapix
  • Class Heart failure therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Myocardial infarction
  • Preclinical Ventricular tachycardia

Most Recent Events

  • 17 Jun 2016 Efficacy and adverse events data from the CAREMI phase I/II trial in Myocardial infarction released by TiGenix
  • 12 Apr 2016 TiGenix completes enrolment in its phase I/II CAREMI trial for Myocardial infarction in Belgium and Spain
  • 23 Sep 2015 Efficacy and adverse events data from the phase I/II CAREMI trial in Myocardial infarction presented at the Congress of the European Society of Cardiology (ESS-Card-2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top